(News Bulletin 247) – GSK welcomed on Friday the rejection by Canadian justice of a class action petition that had been presented in the context of the Zantac case, which supported the title on the London Stock Exchange.
The British biopharmaceutical group indicates that the Supreme Court of British Columbia has pronounced a decision of inadmissibility of a class action brought by Canadian patients who took this drug against heartburn previously marketed by GSK.
According to GSK, the Court justified its judgment by ‘the absence of evidence establishing that ranitidine or the presence of an impurity (NDMA) caused cases of cancer in humans’.
Since 2019, 13 peer-reviewed epidemiological studies on the use of ranitidine have been conducted, without being able to demonstrate a link between the consumption of the molecule and the risk of cancer, adds the laboratory.
In its press release, GSK expresses its intention to defend itself vigorously against the class actions also filed in Ontario and Quebec.
Note that GSK also announced that it had placed on the market 240 million ordinary shares of its former subsidiary of consumer health products, Haleon, for an amount of 804 million pounds.
Following this operation, GSK only holds 10.3% of the company.
On the London Stock Exchange, GSK shares rose 1.8% on Friday in the wake of these announcements, signing one of the strongest increases in the FTSE 100 index.
Copyright (c) 2023 News Bulletin 247. All rights reserved.
I have over 8 years of experience working in the news industry. I have worked as a reporter, editor, and now managing editor at 247 News Agency. I am responsible for the day-to-day operations of the news website and overseeing all of the content that is published. I also write a column for the website, covering mostly market news.
